See more : ONEOK, Inc. (0KCI.L) Income Statement Analysis – Financial Results
Complete financial analysis of SQZ Biotechnologies Company (SQZB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of SQZ Biotechnologies Company, a leading company in the Biotechnology industry within the Healthcare sector.
- Omax Autos Limited (OMAXAUTO.BO) Income Statement Analysis – Financial Results
- GS Acquisition Holdings Corp II (GSAH-UN) Income Statement Analysis – Financial Results
- International Daleco Corp. (ILDO) Income Statement Analysis – Financial Results
- Elgi Equipments Limited (ELGIEQUIP.NS) Income Statement Analysis – Financial Results
- M. K. Proteins Limited (MKPL.BO) Income Statement Analysis – Financial Results
SQZ Biotechnologies Company (SQZB)
About SQZ Biotechnologies Company
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 21.48M | 27.10M | 21.00M | 20.11M | 12.67M |
| Cost of Revenue | 11.68M | 11.03M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 9.79M | 16.07M | 21.00M | 20.11M | 12.67M |
| Gross Profit Ratio | 45.60% | 59.30% | 100.00% | 100.00% | 100.00% |
| Research & Development | 69.48M | 68.94M | 51.55M | 36.10M | 24.38M |
| General & Administrative | 26.32M | 25.72M | 20.51M | 18.27M | 0.00 |
| Selling & Marketing | -10.18M | -9.82M | -10.94M | -4.36M | 0.00 |
| SG&A | 16.14M | 15.90M | 9.57M | 13.92M | 7.63M |
| Other Expenses | 0.00 | -8.00K | -13.00K | -7.00K | 0.00 |
| Operating Expenses | 85.62M | 84.84M | 61.11M | 50.02M | 32.01M |
| Cost & Expenses | 97.30M | 95.87M | 72.06M | 54.37M | 33.07M |
| Interest Income | 1.22M | 36.00K | 550.00K | 2.07M | 978.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 59.00K |
| Depreciation & Amortization | 11.68M | 11.03M | 10.94M | 4.36M | 1.07M |
| EBITDA | -64.14M | -57.74M | -40.12M | -29.91M | -18.18M |
| EBITDA Ratio | -298.64% | -213.07% | -191.04% | -148.73% | -152.63% |
| Operating Income | -75.83M | -68.77M | -51.06M | -34.27M | -20.40M |
| Operating Income Ratio | -353.04% | -253.78% | -243.16% | -170.40% | -161.05% |
| Total Other Income/Expenses | -3.64M | 28.00K | 537.00K | 2.06M | 1.15M |
| Income Before Tax | -79.46M | -68.74M | -50.52M | -32.20M | -19.25M |
| Income Before Tax Ratio | -369.98% | -253.68% | -240.60% | -160.14% | -151.95% |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 984.00K |
| Net Income | -79.46M | -68.74M | -50.52M | -32.20M | -20.23M |
| Net Income Ratio | -369.98% | -253.68% | -240.60% | -160.14% | -159.71% |
| EPS | -2.76 | -2.49 | -2.04 | -1.31 | -0.82 |
| EPS Diluted | -2.76 | -2.49 | -2.04 | -1.31 | -0.82 |
| Weighted Avg Shares Out | 28.81M | 27.58M | 24.79M | 24.63M | 24.63M |
| Weighted Avg Shares Out (Dil) | 28.81M | 27.58M | 24.79M | 24.63M | 24.63M |
STEMCELL Technologies Announces Successful Asset Purchase Agreement with SQZ Biotechnologies Company
Asset Sale and Plan of Liquidation and Dissolution Approved by SQZB Shareholders
SQZ Biotechnologies Reports Third Quarter 2023 Financial Results and Recent Portfolio Updates
SQZ Biotechnologies Reports Data for Clinical Programs at the Society for Immunotherapy of Cancer Annual Meeting
SQZ Biotechnologies Reports Second Quarter 2023 Financial Results and Recent Portfolio Updates
Source: https://incomestatements.info
Category: Stock Reports